GB9024617D0 — Heterocyclic compounds
Assigned to Imperial Chemical Industries Ltd · Expires 1991-01-02 · 35y expired
What this patent protects
This invention concerns novel compounds of the formula I: <CHEM> in which P is a group of formula II or a group of formula III; R<1> is alkyl, cycloalkyl, cycloalkylalkyl, phenyl or phenylalkyl; R<2> is hydrogen, alkyl, amino or alkylamino; R<3> and R<4…
USPTO Abstract
This invention concerns novel compounds of the formula I: <CHEM> in which P is a group of formula II or a group of formula III; R<1> is alkyl, cycloalkyl, cycloalkylalkyl, phenyl or phenylalkyl; R<2> is hydrogen, alkyl, amino or alkylamino; R<3> and R<4> are independently hydrogen, alkyl, phenyl or benzyl; R<6> is alkyl, amino or alkylamino; C and D are independently ethylene or trimethylene; Z is a direct bond between C and D, or an oxy, thio, carbonyl, methylene, ethylenedioxymethylene, ethylidene, or isopropylidene link, or Z is a group of the formula = N.R<5> in which R<5> is alkyl, phenyl or benzyl; R8 is hydrogen, cycloalkylalkyl, alkyl, alkenyl, alkynyl or phenylalkyl; or R8 is a alkylene or alkenylene linked to the nitrogen atom of the group Q.A.N-, either of which linking groups may optionally bear a alkyl, phenyl or phenylalkyl substituent and either of which linking groups thereby completes a ring including two adjacent carbon atoms of ring Q, any carbon atoms in A and the adjacent nitrogen atom of the group -A.N-; A is a direct bond to the the group -N(R8)- or is alkylene; Q is a phenyl or pyridyl moiety; Y is a physiologically acceptable anion; and wherein any one or more of said phenyl, benzene or pyridyl moieties may optionally be unsubstituted or bear one or more selected substituents. The invention also includes certain closely related anhydo-base derivatives which, like the compounds of formula I, possess beneficial effects on the cardiovascular system (and in particular beneficial effects modulated via the sino-atrial node). Also included are pharmaceutical compositions containing compounds of formula I (or a related anhydro-base) as active ingrdient, and processes for the manufacrture of the various novel compounds.
Drugs covered by this patent
- Abilify (aripiprazole) · Generic (originally Otsuka/BMS)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.